Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Current Pharmaceutical Design|December 17, 2008
Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systemsS D Laufer, T RestleFEBS Letters|October 7, 1991
Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivoR S Goody, B Müller, T RestleThe Journal of Biological Chemistry|June 5, 1990
Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic interventionT Restle, B Müller, R S GoodyFEBS Letters|March 23, 1992
RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric formsT Restle, B Müller, R S GoodyFEBS Letters|June 14, 1993
Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescenceG Divita, T Restle, R S GoodyThe EMBO Journal|August 4, 1998
The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitorJ Jaeger, T Restle, T A SteitzNature|June 15, 1989
RNA helicase activity associated with the human p68 proteinH Hirling, M Scheffner, T Restle, et al.The Journal of Biological Chemistry|August 5, 1991
Expression of the heterodimeric form of human immunodeficiency virus type 2 reverse transcriptase in Escherichia coli and characterization of the enzymeB Müller, T Restle, H Kühnel, et al.Biochemistry|April 16, 1991
Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptaseB Müller, T Restle, J Reinstein, et al.Journal of Molecular Biology|September 24, 1999
Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrateB M Wöhrl, R Krebs, R S Goody, et al.Pageof 3